Avalo Therapeutics Inc (NASDAQ: AVTX) stock closed at $7.58 on 1/23/25 after a major increase of 15.0%. Moreover, this advance was accompanied by above average trading volume at 138% of normal. The stock has risen 16.3% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Avalo Therapeutics has a slightly negative Appreciation Score of 40 and a poor Power Rating of 17, triggering the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment